Ilaris 150 mg

ILARIS 150 MG is a subcutaneous solution containing canakinumab, used for managing inflammatory conditions. This medication is designed to target specific proteins involved in the body's immune response.

ILARIS 150 MG is primarily used for the treatment of certain inflammatory conditions. Canakinumab works by targeting specific proteins that play a role in the body's immune response, helping to reduce inflammation. This medication is often prescribed for conditions where excessive inflammation occurs, such as in autoimmune disorders.

Common effects of ILARIS 150 MG may include injection site reactions, such as redness, swelling, or itching. Some individuals might experience fatigue, headache, or upper respiratory infections. These effects vary among users and are not exhaustive.

ILARIS 150 MG should be handled with care, following the healthcare provider's instructions. It is important to store the medication properly and use it as directed. Individuals with known allergies to canakinumab or any of its components should avoid using this medication.

ILARIS 150 MG may interact with other medications, including those that affect the immune system. It is advisable to consult a healthcare provider before combining it with other treatments. Alcohol and certain supplements might also influence its effectiveness or side effects.